Glipizide — Sulfonylurea. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Glipizide
Class
Sulfonylurea
Mechanism
Appears to lower glucose acutely by stimulating insulin release from functioning pancreatic beta cells; the mechanism of glucose lowering during long-term treatment is not clearly established.
Used for
Type 2 diabetes in adults, as an adjunct to diet and exercise
Hypoglycemia; Contraindicated in type 1 diabetes / DKA; Hypersensitivity to glipizide; The label carries a cardiovascular-mortality warning based on a tolbutamide study and advises considering its possible applicability to other sulfonylureas
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260827 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
On both cards: Used for — Type 2 diabetes in adults, as an adjunct to diet and exercise · Common side effects — Nausea
Only on the Glimepiride card: Common side effects — Hypoglycemia; Headache; Dizziness; Asthenia · Warnings — Severe hypoglycemia; Hypersensitivity incl. sulfonamide allergy; Hemolytic anemia in G6PD deficiency · Interactions — Oral miconazole (severe hypoglycemia); CYP2C9 inhibitors and inducers; Colesevelam
Mechanism: GLP-1 analogue that selectively binds and activates the GLP-1 receptor; albumin binding gives it a long half-life.
On both cards: Common side effects — Nausea; Diarrhea; Constipation
Only on the Semaglutide card: Used for — As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; Reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; Reduction of sustained eGFR decline, end-stage kidney disease or cardiovascular death in adults with type 2 diabetes and chronic kidney disease · Common side effects — Vomiting; Abdominal pain · Warnings — Acute pancreatitis; Diabetic retinopathy complications; Hypoglycemia with insulin or secretagogues · Interactions — Insulin secretagogues (e.g. sulfonylureas); Insulin; Oral medications (delayed gastric emptying)
Mechanism: Activates both GIP and GLP-1 receptors; GLP-1 regulates appetite and caloric intake. A fatty diacid prolongs half-life.
On both cards: Common side effects — Nausea; Diarrhea; Constipation
Only on the Tirzepatide card: Used for — With reduced-calorie diet and increased physical activity, long-term weight reduction/maintenance in adults with obesity or overweight plus at least one weight-related comorbidity; With reduced-calorie diet and increased physical activity, moderate-to-severe obstructive sleep apnea in adults with obesity · Common side effects — Vomiting; Abdominal pain · Warnings — Severe GI adverse reactions; Acute pancreatitis; Acute gallbladder disease · Interactions — Insulin or sulfonylureas; Oral medications (delayed gastric emptying)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera